Report: Big Pharmas R&D Strategy In Oncology & Breast & Prostate Cancer TOC

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Tables
3.2 List of Boxes

4 Big Pharma' s R&D Position and Strategy in Oncology: A Summary

4.1 Bristol-Myers Squibb
4.2 GlaxoSmithKline
4.3 Hoffmann-La Roche
4.4 Novartis
4.5 Sanofi-Aventis

5 Last Five Years of Deals and Alliances in Oncology

5.1 Bristol Myers Squibb
- 5.1.1 Discovery and Lead Molecule Improvements
- 5.1.2 Adding Image Analysis to Support Clinical Trials and Early Diagnosis
- 5.1.3 Bladder Cancer and Melanoma Registration Filings are Emminent
- 5.1.4 The Human Kinome and Cell Cycle Inhibitors
- 5.1.5 Strategic Priorities in Pipeline Development Leads to Divestments
- 5.1.6 Erbitux Expansion is Set to Challenge Avastin
5.2 GlaxoSmithKline
- 5.2.1 The Biopharmaceutical Strategy at GSK
- 5.2.2 Out Goes Classes of Small Molecule Inhibitors
- 5.2.3 Marketing and Manufacturing Collaborations
- 5.2.4 Patient Selectionfo r GSK' s Targeted Cancer Therapies
- 5.2.5 GSK Taping Into Knowledge Databases
- 5.2.6 Increasing the Oral Bioavailability Cytotoxic Oncology Drugs
- 5.2.7 Oxford University Helps GSK in India
- 5.2.8 GSK is Set to Improve Medical Imaging
5.3 Hoffmann-La Roche
- 5.3.1 Roche Builds Center of Excellence for RNAi Therapeutics Discovery
- 5.3.2 A New Delivery Route for Avastin?
- 5.3.3 Improving Antibody Drugs
- 5.3.4 Roche Strengthens Presence in Genomics Research Market
- 5.3.5 Target Validation
- 5.3.6 Drug Discovery Collaborations
- 5.3.7 Marketing
- 5.3.8 Outlicensing
- 5.3.9 Size Doesn' t Matter: Genentech' s Goal of Aggressively Pursuing Novel and Innovative Therapies
5.4 Novartis
- 5.4.1 Novartis Acquisition of Chiron: A Major Biopharmaceutical Investment
- 5.4.2 Protein Kinase Inhibitors
- 5.4.3 Next Generation Oral Topoisomerase Inhibitor and Telomerase Promotors
- 5.4.4 Novartis Sells of World-Wide Rights
- 5.4.5 Biomarker and Proteomics Research
5.5 Sanofi-Aventis
- 5.5.1 Target Screening and Validation
- 5.5.2 Biologicals
- 5.5.3 A Short Cut to Success?
- 5.5.4 Aventis Divests Interest
- 5.5.5 Recombine My Molecule

6 Competitive R&D Comparison on Oncology Drug Target Level

6.1 Target Overview
6.2 Head to Head Target Comparison by Molecular Function and Cancer Type
- 6.2.1 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- 6.2.2 Receptor Activity Targets
- 6.2.3 G-protein Coupled Receptor Activity Targets
- 6.2.4 Protein Serine/Threonine Kinase Activity Targets
- 6.2.5 Transcription Factor Activity Targets
- 6.2.6 Transmembrane Receptor Activity Targets
- 6.2.7 Catalytic Activity Targets
- 6.2.8 Cytokine Activity Targets
- 6.2.9 Protein-Tyrosine Kinase Activity Targets
- 6.2.10 Kinase Activity Targets
- 6.2.11 DNA Topoisomerase Activity Targets
- 6.2.12 Growth Factor Activity Targets
- 6.2.13 Ligase Activity Targets
- 6.2.14 Motor Activity Targets
- 6.2.15 Structural Constituent of Cytoskeleton Targets
- 6.2.16 Transporter Activity Targets
- 6.2.17 Targets According to Miscellaneous Molecular Function Groups
- 6.2.18 Unclassified or Unknown Molecular Function of Targets
6.3 Drug Targets by Target Localization and Compound Type
6.4 Targets, Drugs and Cancer Indications Linked to Signaling Pathways
- 6.4.1 Alpha6 Beta4 Integrin Signaling Pathway
- 6.4.2 Androgen Receptor Signaling Pathway
- 6.4.3 B Cell Receptor Signaling Pathway
- 6.4.4 EGFR1 Signaling Pathway
- 6.4.5 Hedgehog Signaling Pathway
- 6.4.6 ID Signaling Pathway
- 6.4.7 IL-1 Signaling Pathway
- 6.4.8 IL-2 Signaling Pathway
- 6.4.9 IL-3 Signaling Pathway
- 6.4.10 IL-4 Signaling Pathway
- 6.4.11 IL-5 Signaling Pathway
- 6.4.12 IL-6 Signaling Pathway
- 6.4.13 IL-9 Signaling Pathway
- 6.4.14 Kit Receptor Signaling Pathway
- 6.4.15 Notch Signaling Pathway
- 6.4.16 T Cell Receptor Signaling Pathway
- 6.4.17 TGF-beta Receptor Signaling Pathway
- 6.4.18 TNF-alpha Signaling Pathway
- 6.4.19 Wnt Signaling Pathway

7 Drug Compound Type Analysis

7.1 Deployment of Biological Based Compounds by Cancer Indications
7.2 Deployment of Chemical Based Compounds by Cancer Indications
7.3 Deployment of Natural Product Compounds by Cancer Indications

8 Drug Development in Oncology by Major Targeted Therapy Areas

8.1 Angiogenesis
8.2 Antibodies
8.3 Apoptosis
8.4 Protein Kinase Inhibitors
8.5 Vaccines

9 Cancer Indication Focus Analysis

9.1 Preclinical Stage Pipeline
9.2 Phase I Clinical Stage Pipeline
9.3 Phase II Clinical Stage Pipeline
9.4 Phase III Clinical Stage Pipeline
9.5 Drugs Soon to be on the Market
9.6 Approved Drugs

10 Breast Cancer: An Introduction

10.1 Disease Definitions
10.2 Etiology
10.3 Epidemiology
10.4 Prognosis

11 Current Treatment Strategies of Breast cancer

11.1 Localized Disease
11.2 Advanced Disease

12 Progress in Current Breast Cancer Treatment Strategies

12.1 Hormone Based Therapies
12.2 Antibodies
12.3 Chemotherapy
12.4 Chemotherapy

13 Key Therapeutic Strategies for Future Breast Cancer Therapies

13.1 Therapeutic Type, Targets & Mechanisms

14 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

14.1 The Epothilones
14.2 Cell Cycle & Apoptosis
14.3 Protein Kinase Inhibitors
14.4 Immunotherapy

15 Current Drug Development for Breast Cancer: The Early Stage Pipeline

15.1 DNA Targeting
15.2 FTIs
15.3 Antisense
15.4 New Hormone Modulators
15.5 Other

16 Prostate Cancer: An Introduction

16.1 Disease Definitions
16.2 Etiology & Pathophysiology
16.3 Epidemiology
16.4 Prognosis

17 Current Prostate Cancer Treatment Strategies

17.1 Localized Disease
- 17.1.1 Locally Advanced Prostate Cancer
17.2 Metastatic Prostate Cancer
- 17.2.1 Hormone-Sensitive Metastatic Prostate Cancer
- 17.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

18 Progress in Current Prostate Cancer Treatment Strategies

18.1 Long-Term Follow-up Data not yet Been Published
18.2 Significant Reduced Risk of Distant Metastases
18.3 Adverse Events
18.4 No Difference in Overall Survival
18.5 Cross-over Design an Optimal Option?
18.6 Death due to Liver Failure
18.7 Survival Benefit
18.8 Subdermal Implant
18.9 No FDA Approval
18.10 No Improvement in 5-year Disease-Free Survival
18.11 Effective Secondary Hormonal Therapy?
18.12 Synery in Combination

19 Key Therapeutic Strategies for Future Prostate Cancer Therapies

19.1 Therapeutic Type, Targets & Mechanisms

20 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

20.1 Reduced Prostate Cancer Risk
20.2 High Activity in Metastatic AIPC Patients
20.3 Absence of Severe Toxicities
20.4 Waiting for Data
20.5 Probability of Regulatory Approval?
20.6 Co-development and License Agreement
20.7 Improves Predicted Survival?
20.8 Slow Progress & Development Partners
20.9 Exclusive License Agreement

21 Current Prostate Cancer Drug Development: The Early Stage Pipeline

21.1 New Data?
21.2 Terminated Study
21.3 More Than 50% PSA decline
21.4 Safety and Tolerability
21.5 Terminated?
21.6 Marker of Drug Effect
21.7 Preliminary Results for a Tyrosine Kinase Inhibitor
21.8 No Activity in Monotherapy
21.9 Dramatic Disappearance of Bone Metastatic Lesions
21.10 PSA Response - Anthracycline

22 Disclaimer

23 Drug Index

24 Company Index

List of Tables

Table 1: How to Navigate the Report
Table 2: Number of Pursued Oncology Drugs Targets by Company
Table 3: Pursued Oncology Drugs Targets by Molecular Function
Table 4: Drug Target Expression Profiles in Humans
Table 5: Identified Targets By Cancer Indications
Table 6: Head to Head Comparison of Drugs with Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
Table 7: Head to Head Comparison of Drugs with Receptor Activity Targets
Table 8: Head to Head Comparison of Drugs with G-protein Coupled Receptor Activity
Table 9: Head to Head Comparison of Drugs with Protein Serine/Threonine Kinase Activity
Table 10: Head to Head Comparison of Drugs with Transcription Factor Activity Targets
Table 11: Head to Head Comparison of Drugs with Transmembrane Receptor Activity Targets
Table 12: Head to Head Comparison of Drugs with Catalytic Activity Targets
Table 13: Head to Head Comparison of Drugs with Cytokine Activity Targets
Table 14: Head to Head Comparison of Drugs with Protein-Tyrosine Kinase Activity Targets
Table 15: Head to Head Comparison of Drugs with Kinase Activity Targets
Table 16: Head to Head Comparison of Drugs with DNA Topoisomerase Activity Targets
Table 17: Head to Head Comparison of Drugs with Growth Factor Activity Targets
Table 18: Head to Head Comparison of Drugs with Ligase Activity Targets
Table 19: Head to Head Comparison of Drugs with Motor Activity Targets
Table 20: Head to Head Comparison of Drugs with Structural Constituent of Cytoskeleton Targets
Table 21: Head to Head Comparison of Drugs with Transporter Activity Targets
Table 22: Head to Head Comparison of Drugs with Targets According to Miscellaneous Molecular Function Groups
Table 23: Head to Head Comparison of Drugs with Unclassified or Unknown Molecular Function Targets
Table 24: Drug Target Comparison by Target Localization and Compound Type
Table 25: Targeting Signaling Pathways: An Overview
Table 26: Targeted Signaling Pathway Profiles of Big Pharma
Table 27: Targets, Drugs and Cancer Indications Linked to the Alpha6 Beta4 Integrin Signaling Pathway
Table 28: Targets, Drugs and Cancer Indications Linked to the Androgen Receptor Signaling Pathway
Table 29: Targets, Drugs and Cancer Indications Linked to the B Cell Receptor Signaling Pathway
Table 30: Targets, Drugs and Cancer Indications Linked to the EGFR1 Signaling Pathway
Table 31: Targets, Drugs and Cancer Indications Linked to the Hedgehog Signaling Pathway
Table 32: Targets, Drugs and Cancer Indications Linked to the ID Signaling Pathway
Table 33: Targets, Drugs and Cancer Indications Linked to the IL-1 Signaling Pathway
Table 34: Targets, Drugs and Cancer Indications Linked to the IL-3 Signaling Pathway
Table 35: Targets, Drugs and Cancer Indications Linked to the IL-4 Signaling Pathway
Table 36: Targets, Drugs and Cancer Indications Linked to the IL-5 Signaling Pathway
Table 37: Targets, Drugs and Cancer Indications Linked to the IL-6 Signaling Pathway
Table 38: Targets, Drugs and Cancer Indications Linked to the Kit Receptor Signaling Pathway
Table 39: Targets, Drugs and Cancer Indications Linked to the Notch Signaling Pathway
Table 40: Targets, Drugs and Cancer Indications Linked to the T Cell Receptor Signaling Pathway
Table 41: Targets, Drugs and Cancer Indications Linked to the TGF-beta Receptor Signaling Pathway
Table 42: Targets, Drugs and Cancer Indications Linked to the TNF-alpha Signaling Pathway
Table 43: Targets, Drugs and Cancer Indications Linked to the Wnt Signaling Pathway
Table 44: Deployment of Biological Based Compounds by Cancer Indications
Table 45: Deployment of Chemical Based Compounds by Cancer Indications
Table 46: Deployment of Natural Product Based Compounds by Cancer Indications
Table 47: Comparative Presentation of Targeted Therapy Areas in Oncology
Table 48: The Angiogenesis Pipeline by Cancer Type and Developmental Stage
Table 49: The Antibody Pipeline by Cancer Type and Developmental Stage
Table 50: The Apoptosis Pipeline by Cancer Type and Developmental Stage
Table 51: The Protein Kinase Inhibitor Pipeline by Cancer Type and Developmental Stage
Table 52: The Cancer Vaccine Pipeline by Cancer Type and Developmental Stage
Table 53: Summary of Big Pharma' s Preclinical Stage Pipeline
Table 54: Preclinical Stage Pipeline by Cancer Indications
Table 55: Summary of Big Pharma' s Phase I Clinical Stage Pipeline
Table 56: : Phase I Clinical Stage Pipeline by Cancer Indications
Table 57: Summary of Big Pharma' s Phase II Clinical Stage Pipeline
Table 58: Phase II Clinical Stage Pipeline by Cancer Indications
Table 59: Summary of Big Pharma' s Phase III Clinical Stage Pipeline
Table 60: Phase III Clinical Stage Pipeline by Cancer Indications
Table 61: Oncology Drugs Soon to be on the Market
Table 62: Summary of Big Pharma' s Approved Oncology Drugs
Table 63: Approved Drugs by Cancer Indications
Table 105: The Stage System
Table 106: Risk Factors
Table 107: List of Approved Drugs and Their Mechanisms of Action.
Table 108: Hormonal Treatment Strategies
Table 109: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer
Table 110: Treatment Options for Women With Axillary Node-Positive Breast Cancer
Table 111: Chemotherapy Drugs and Regimen
Table 112: Summay of Drugs Involved in Breast Cancer Therapy
Table 113: Short Facts Tamoxifen
Table 114: Short Facts Anastrozole
Table 115: Short Facts Letrozole
Table 116: Short Facts Exemestane
Table 117: Short Facts Goserelin
Table 118: Short Facts Fulvestrant
Table 119: Short Facts Trastuzumab
Table 120 Cancer Immunotherapy Strategies
Table 121: Progress on Ixabepilone
Table 122: Progress on CCI-779
Table 123: Progress on Fenretinide
Table 124: Progress on Lapatinib
Table 125: Progress on Bevacizumab
Table 126: Progress on Theratope
Table 127: Summary of Mid-Stage to Late stage Investigational Agents Under Development
Table 128: Summary of Breast Cancer Early Stage Pipeline
Table 129: The TNM System
Table 130: Lifestyle factors
Table 131: Historical Summary of Clinical Studies on Patients with Late Stage Disease
Table 132: Short Facts Abarelix
Table 133: Short Facts Bicalutamide
Table 134: Short Facts Carboplatin
Table 135: Short Facts Docetaxel
Table 136: Short Facts Mitoxantrone
Table 137: Short Facts Flutamide
Table 138: Short Facts Goserelin
Table 139: Short Facts Histrelin
Table 140: Short Facts Lanreotide
Table 141: Short Facts Leuprolide
Table 142: Short Facts Nilutamide
Table 143: Short Facts Estramustine
Table 144: Summary of Recent Clinical Studies on Patients with Late Stage Disease
Table 145: Ongoing Late Stage Clinical Studies
Table 146: Cancer Immunotherapy Strategies
Table 147: Near Term Progress Toremifene
Table 148: Near Term Progress Bevacizumab
Table 149: Near Term Progress Oblimersen
Table 150: Near Term Progress R-flurbiprofen
Table 151: Near Term Progress APC8015
Table 152: Near Term Progress Satraplatin
Table 153: Near Term Progress GVAX
Table 154: Near Term Progress Exisulind
Table 155: Summary of Prostate Cancer Late Stage Pipeline
Table 156: Paclitaxel
Table 157: Epothilone
Table 158: Ixabepilone
Table 159: PTK/ZK
Table 160: Arsenic trioxide
Table 161: Retinoic Acid
Table 162: Imatinib
Table 163: Bortezomib
Table 164: Sorafenib
Table 165: Doxorubicin
Table 166: Summary of Prostate Cancer Early Stage Pipeline

List of Boxes

Box 1: Ongoing Phase III Studies Anastrozole
Box 2: Ongoing Phase III Studies Letrozole
Box 3: Ongoing Phase III Studies Exemestane
Box 4: Ongoing Phase III Studies Goserelin
Box 5: Ongoing Phase III Studies Fulvestrant
Box 6: Ongoing Phase III Studies Trastuzumab
Box 7: The TRAIL Receptor family
Box 8: The Bcl-2 family of proteins
Box 9: Quick Facts - BMS-247550
Box 10: Quick Facts - Temsirolimus
Box 11: Quick Facts - SDX-105
Box 12: Quick Facts - 4HPR
Box 13: Quick Facts - Lapatinib
Box 14: Quick Facts - Bevacizumab
Box 15: Quick Facts - Theratope
Box 16: Erlotinib
Box 17: Gefitinib
Box 18: Imatinib
Box 19: Pemetrexed
Box 20: NX473
Box 21: Lonafarnib
Box 22: Tipifarnib
Box 23: Bortezomib
Box 24: Arzoxifene
Box 25: Patupilone
Box 26: KOS-862
Box 27: Southwest Oncology Group Study 99-16 Design
Box 28: TAX 327 Study Design
Box 29: The TRAIL Receptor family
Box 30: The Bcl-2 family of proteins
Box 31: Quick Facts - Toremifene
Box 32: Quick Facts - Bevacizumab
Box 33: Quick Facts - Genasense
Box 34: Quick Facts - R-flurbiprofen
Box 35: Quick Facts - Provenge
Box 36: Quick Facts - Satraplatin
Box 37: Quick Facts - GVAX
Box 38: Quick Facts - Exisulind
Box 39: Quick Facts - Vapreotide
Box 40: Quick Facts - DCVax